Basic Information
RNALocate ID: | RLID:11001775 |
RNA Symbol: | hsa-miR-141-3p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-141 |
RNA ID: | miRBase:MIMAT0000432 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23539611 |
Tissue/Cell Line: | Seminal plasma |
Method: | Microarray |
Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001783 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:01001784 | P-body | HeLa cells | 28488892 |
RLID:11001768 | Exosome | Human milk | 28688106 |
RLID:11001769 | Exosome | Pulmonary epithelial cell line (BEAS-2B) | 31520698 |
RLID:11001770 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11001771 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001772 | Exosome | Renal cancer cells | 21670082 |
RLID:11001773 | Exosome | Brain tissue | 23382797 |
RLID:11001774 | Exosome | Plasma | 23663360 |
RLID:21000268 | Cytoplasmic stress granule | HeLa cells | 28488892 |
RLID-D:11000082 | Exosome | Breast milk|Colon tissue|Seminal fluid | |
RLID-D:11000360 | Microvesicle | Colon cancer cell line (LIM1863)|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-141-3p | Splenic marginal zone lymphoma | MNDR-E-MI-13652 |
MNDR | hsa-miR-141-3p | Renal fibrosis | MNDR-E-MI-13653 |
MNDR | hsa-miR-141-3p | Oral squamous cell carcinoma | MNDR-E-MI-13654 |
MNDR | hsa-miR-141-3p | Large cell neuroendocrine cancer | MNDR-E-MI-13655 |
MNDR | hsa-miR-141-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-13656 |
MNDR | hsa-miR-141-3p | Ovarian clear cell carcinoma | MNDR-E-MI-13657 |
MNDR | hsa-miR-141-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-13658 |
MNDR | hsa-miR-141-3p | Lymphoma | MNDR-E-MI-13659 |
MNDR | hsa-miR-141-3p | Lymphoma non-hodgkin | MNDR-E-MI-13660 |
MNDR | hsa-miR-141-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-13661 |
MNDR | hsa-miR-141-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-13662 |
MNDR | hsa-miR-141-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-13663 |
MNDR | hsa-miR-141-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-13664 |
MNDR | hsa-miR-141-3p | Her2-receptor positive breast cancer | MNDR-E-MI-13665 |
MNDR | hsa-miR-141-3p | Breast cancer luminal | MNDR-E-MI-13666 |
MNDR | hsa-miR-141-3p | Dermatomyositis | MNDR-E-MI-13667 |
MNDR | hsa-miR-141-3p | Prostate cancer | MNDR-E-MI-13668 |
MNDR | hsa-miR-141-3p | Gastric cancer | MNDR-E-MI-13669 |
MNDR | hsa-miR-141-3p | Gastric lymphoma | MNDR-E-MI-13670 |
MNDR | hsa-miR-141-3p | Alzheimer disease | MNDR-E-MI-13671 |
MNDR | hsa-miR-141-3p | Sickle cell anemia | MNDR-E-MI-13672 |
MNDR | hsa-miR-141-3p | Bladder cancer | MNDR-E-MI-13673 |
MNDR | hsa-miR-141-3p | Esophageal carcinoma | MNDR-E-MI-13674 |
MNDR | hsa-miR-141-3p | Dysautonomia familial | MNDR-E-MI-13675 |
MNDR | hsa-miR-141-3p | Head and neck cancer | MNDR-E-MI-13676 |
MNDR | hsa-miR-141-3p | Huntington disease | MNDR-E-MI-13677 |
MNDR | hsa-miR-141-3p | Chorea | MNDR-E-MI-13678 |
MNDR | hsa-miR-141-3p | Cardiovascular disease | MNDR-E-MI-13679 |
MNDR | hsa-miR-141-3p | Lung cancer | MNDR-E-MI-13680 |
MNDR | hsa-miR-141-3p | Endometrial cancer | MNDR-E-MI-13681 |
MNDR | hsa-miR-141-3p | Parkinson disease | MNDR-E-MI-13682 |
MNDR | hsa-miR-141-3p | Breast cancer | MNDR-E-MI-13683 |
MNDR | hsa-miR-141-3p | Cancer | MNDR-E-MI-13684 |
MNDR | hsa-miR-141-3p | Thyroid cancer | MNDR-E-MI-13685 |
MNDR | hsa-miR-141-3p | Pituitary neoplasms | MNDR-E-MI-13686 |
MNDR | hsa-miR-141-3p | Pancreatic cancer | MNDR-E-MI-13687 |
MNDR | hsa-miR-141-3p | Melanoma | MNDR-E-MI-13688 |
MNDR | hsa-miR-141-3p | Rectum adenocarcinoma | MNDR-E-MI-13689 |
MNDR | hsa-miR-141-3p | Nephroblastoma | MNDR-E-MI-13690 |
MNDR | hsa-miR-141-3p | Colon cancer | MNDR-E-MI-13691 |
MNDR | hsa-miR-141-3p | Ischemic attack transient | MNDR-E-MI-13692 |
MNDR | hsa-miR-141-3p | Colon adenocarcinoma | MNDR-E-MI-13693 |
MNDR | hsa-miR-141-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-13694 |
MNDR | hsa-miR-141-3p | Familial ovarian cancer | MNDR-E-MI-13695 |
MNDR | hsa-miR-141-3p | Prostate adenocarcinoma | MNDR-E-MI-13696 |
MNDR | hsa-miR-141-3p | Kidney neoplasms | MNDR-E-MI-13697 |
MNDR | hsa-miR-141-3p | Endometrial endometrioid carcinoma | MNDR-E-MI-13698 |
MNDR | hsa-miR-141-3p | Carcinoma ductal breast | MNDR-E-MI-13699 |
MNDR | hsa-miR-141-3p | Glioblastoma | MNDR-E-MI-13700 |
MNDR | hsa-miR-141-3p | Glioma | MNDR-E-MI-13701 |
MNDR | hsa-miR-141-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-13702 |
MNDR | hsa-miR-141-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-13703 |
MNDR | hsa-miR-141-3p | Epilepsy temporal lobe | MNDR-E-MI-13704 |
MNDR | hsa-miR-141-3p | Osteosarcoma | MNDR-E-MI-13705 |
MNDR | hsa-miR-141-3p | Liposarcoma | MNDR-E-MI-13706 |
MNDR | hsa-miR-141-3p | Breast carcinoma | MNDR-E-MI-13707 |
MNDR | hsa-miR-141-3p | Liver neoplasms | MNDR-E-MI-13708 |
MNDR | hsa-miR-141-3p | Choriocarcinoma | MNDR-E-MI-13709 |
MNDR | hsa-miR-141-3p | Uterine cancer | MNDR-E-MI-13710 |
MNDR | hsa-miR-141-3p | Cervical adenocarcinoma | MNDR-E-MI-13711 |
MNDR | hsa-miR-141-3p | Gastric adenocarcinoma | MNDR-E-MI-13712 |
MNDR | hsa-miR-141-3p | Cervical squamous cell carcinoma | MNDR-E-MI-13713 |
MNDR | hsa-miR-141-3p | Pituitary adenoma | MNDR-E-MI-13714 |
MNDR | hsa-miR-141-3p | Lung squamous cell carcinoma | MNDR-E-MI-13715 |
MNDR | hsa-miR-141-3p | Non-small cell lung adenocarcinoma | MNDR-E-MI-13716 |
MNDR | hsa-miR-141-3p | Lung adenocarcinoma | MNDR-E-MI-13717 |
MNDR | hsa-miR-141-3p | Adrenocortical carcinoma | MNDR-E-MI-13718 |
MNDR | hsa-miR-141-3p | Thyroid carcinoma | MNDR-E-MI-13719 |
MNDR | hsa-miR-141-3p | Ovarian carcinoma | MNDR-E-MI-13720 |
MNDR | hsa-miR-141-3p | Bladder urothelial carcinoma | MNDR-E-MI-13721 |
MNDR | hsa-miR-141-3p | Carcinoma renal cell | MNDR-E-MI-13722 |
MNDR | hsa-miR-141-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-13723 |
MNDR | hsa-miR-141-3p | Clear cell renal cell carcinoma | MNDR-E-MI-13724 |
MNDR | hsa-miR-141-3p | Biliary tract cancer | MNDR-E-MI-13725 |
MNDR | hsa-miR-141-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-13726 |
MNDR | hsa-miR-141-3p | Cholangiocarcinoma | MNDR-E-MI-13727 |
MNDR | hsa-miR-141-3p | Lung small cell carcinoma | MNDR-E-MI-13728 |
MNDR | hsa-miR-141-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-13729 |
MNDR | hsa-miR-141-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-13730 |
MNDR | hsa-miR-141-3p | Breast invasive carcinoma | MNDR-E-MI-13731 |
MNDR | hsa-miR-141-3p | Hepatocellular carcinoma | MNDR-E-MI-13732 |
MNDR | hsa-miR-141-3p | Familiar ovarian carcinoma | MNDR-E-MI-13733 |
MNDR | hsa-miR-141-3p | B-cell lymphoma | MNDR-E-MI-13734 |
MNDR | hsa-miR-141-3p | Rheumatoid arthritis | MNDR-E-MI-13735 |
MNDR | hsa-miR-141-3p | Ulcerative colitis | MNDR-E-MI-13736 |
MNDR | hsa-miR-141-3p | Burkitt lymphoma | MNDR-E-MI-13737 |
MNDR | hsa-miR-141-3p | Crohn disease | MNDR-E-MI-13738 |
MNDR | hsa-miR-141-3p | Psoriasis | MNDR-E-MI-13739 |
MNDR | hsa-miR-141-3p | Skin cutaneous melanoma | MNDR-E-MI-13740 |
MNDR | hsa-miR-141-3p | Skin melanoma | MNDR-E-MI-13741 |
MNDR | hsa-miR-141-3p | Acute myelogenous leukemia | MNDR-E-MI-13742 |
MNDR | hsa-miR-141-3p | Colorectal cancer | MNDR-E-MI-13743 |
MNDR | hsa-miR-141-3p | Nasopharyngeal carcinoma | MNDR-E-MI-13744 |
MNDR | hsa-miR-141-3p | Nasopharynx carcinoma | MNDR-E-MI-13745 |
MNDR | hsa-miR-141-3p | Multiple myeloma | MNDR-E-MI-13746 |
MNDR | hsa-miR-141-3p | Ovarian epithelial cancer | MNDR-E-MI-13747 |
MNDR | hsa-miR-141-3p | Esophageal squamous cell carcinoma | MNDR-E-MI-13748 |
MNDR | hsa-miR-141-3p | Uterine cervical neoplasms | MNDR-E-MI-13749 |
MNDR | hsa-miR-141-3p | Ependymoma | MNDR-E-MI-13750 |
MNDR | hsa-miR-141-3p | Nasopharyngeal cancer | MNDR-E-MI-13751 |
MNDR | hsa-miR-141-3p | Prostatic neoplasms | MNDR-E-MI-13752 |
MNDR | hsa-miR-141-3p | Epstein-barr virus infections | MNDR-E-MI-13753 |
MNDR | hsa-miR-141-3p | Brain injury chronic | MNDR-E-MI-13754 |
MNDR | hsa-miR-141-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-13755 |
MNDR | hsa-miR-141-3p | Pituitary acth hypersecretion | MNDR-E-MI-13756 |
MNDR | hsa-miR-141-3p | Breast cancer her3+ negative | MNDR-E-MI-13757 |
MNDR | hsa-miR-141-3p | Low grade dysplastic nodule | MNDR-E-MI-13758 |
MNDR | hsa-miR-141-3p | Renal childhood neoplasms | MNDR-E-MI-13759 |
MNDR | hsa-miR-141-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-13760 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ACVR2B | Homo sapiens | RR00039524 |
TOP